





Travis et al Cardiopulmonary Support and Physiologyascular pulsatility in patients with a pulsatile- or
ontinuous-flow ventricular assist device
dam R. Travis, BE,a Guruprasad A. Giridharan, PhD,a George M. Pantalos, PhD,a Robert D. Dowling, MD,a





































PFrom the Cardiovascular Innovation Insti-
tutea and the Institute of Molecular Cardi-
ology, Department of Medicine,b Univer-
sity of Louisville, Louisville, Ky; Advocate
Christ Medical Center,c Oak Lawn, Ill; the
Departments of Pediatrics, Surgery and
Bioengineering,d Penn State College of
Medicine, Hershey, Pa; and the Thoratec
Corporation,e Pleasanton, Calif.
Funding for this project was provided by
the Jewish Hospital Heart and Lung Re-
search Foundation (Louisville, Ky) and an
equipment grant from Thoratec Corpora-
tion (Pleasanton, Calif).
Robert Dowling reports consulting fees
from Abiomed and Circulite. Guruprasad
Giridharan reports consulting fees from
Abiomed. Steven Koenig reports consulting
fees from Abiomed and grant support from
Thoratec. George Pantalos reports consult-
ing fees from Abiomed and equity owner-
ship in Transonic Systems. Mark Slaughter
reports speaker fees from Thoratec. This
study was reported in part by a grant from
Thoratec.
Received for publication July 7, 2006; re-
visions accepted July 7, 2006; accepted for
publication Sept 25, 2006.
Address for reprints: Steven C. Koenig,
PhD, Cardiovascular Innovation Institute,
University of Louisville, 500 South Floyd
St, Room 118, Department of Surgery, Uni-
versity of Louisville, Louisville, KY 40202
(E-mail: sckoen01@gwise.louisville.edu).
J Thorac Cardiovasc Surg 2007;133:517-24
0022-5223/$32.00
Copyright © 2007 by The American Asso-
ciation for Thoracic Surgerya
doi:10.1016/j.jtcvs.2006.09.057bjective: We sought to investigate differences in indices of pulsatility between patients
ith normal ventricular function and patients with heart failure studied at the time of
mplantation with continuous-flow or pulsatile-flow left ventricular assist devices.
ethods: Eight patients with normal ventricular function and 22 patients with heart
ailure were studied. A high-fidelity aortic and left ventricular pressure catheter was
nserted retrograde through the aortic valve into the left ventricle, and transit-time
ow probes were placed on the aorta and device outflow graft. Hemodynamic
aveforms were recorded at native heart rate before cardiopulmonary bypass and
ver a range of device flow rates controlled by adjusting beat rate or rpm. These data
ere used to calculate vascular input impedance and 2 indices of vascular pulsa-
ility: energy-equivalent pressure and surplus hemodynamic energy.
esults: At low support levels, pulsatile support restored surplus hemodynamic
nergy to within 2.5% of normal values, whereas continuous support diminished
urplus energy by more than 93%. At high support levels, pulsatile support aug-
ented surplus energy by 49% over normal values, whereas continuous support
urther diminished surplus energy by 97%. Pulsatile support diminished vascular
mpedance from baseline failure values, whereas continuous support increased
mpedance. Vascular impedances at baseline for patients undergoing pulsatile and
ontinuous support and during pulsatile support revealed normal vascular compli-
nce, whereas impedance during continuous support indicated a loss of compliance
or “stiffening”) of the vasculature.
onclusion: These results suggest that selection of device type and flow rate can influence
ascular pulsatility and input impedance, which might affect clinical outcomes.
eft ventricular assist device (LVAD) implantation has become a standard
therapeutic measure for bridging to transplantation in patients with end-stage
heart failure and is gaining wider clinical acceptance as destination
herapy in patients ineligible for transplantation, as validated by the results of
he Randomized Evaluation of Mechanical Assistance for the Treatment of
ongestive Heart Failure (REMATCH) study.1 Furthermore, there is hope that
hese devices can be operated in such a way as to promote myocardial recovery
ecause during support, they have been shown to be capable of partially reversing
any of the genetic, functional, and morphological hallmarks of the failing heart, 2-8
n addition to allowing device removal without transplantation in a small fraction of
atients.9 Recent evidence indicates that although there are differences in the
orphology of unloading between pulsatile-flow (PF) and continuous-flow (CF)
umps, both are capable of achieving normalization of cellular damage markers, 10
nd although CF pumps are at an earlier stage in development, they appear to be just
s effective as their older counterparts in bridging patients to transplantation. Given the
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CSPpparent similarity in the general hemodynamic benefit offered
o patients with heart failure by the 2 device types, CF LVADs
re gaining greater acceptance because they have fewer mov-
ng parts and improved mechanical reliability11 and are con-
iderably smaller, minimizing thrombogenic surface area and
nabling implantation in small adults and children.
Amidst the growing popularity of CF LVADs, however,
here remain unanswered questions regarding the appropri-
te level of arterial pulsatility provided when using these
evices. Although limited studies have shown that they
ight be able to provide near-physiological pulsatility at
ime points weeks to months after implantation,12 the degree
f pulsatility achieved in human subjects with CF LVAD
upport has not been rigorously compared with that
chieved with PF LVAD support. Diminished pulsatility
ith CF pumps may have significant implications for end-
rgan function and recovery. Investigators have shown that
ulsatile arterial flow more greatly benefits the peripheral
asculature and vital organs than nonpulsatile perfusion
uring acute or chronic mechanical circulatory support.13
tudies of the consequences of flow character (PF vs CF)
uring cardiopulmonary bypass in adults14,15 have shown
any important advantages of PF over nonpulsatile flow
CF or diminished PF), including decreased systemic and
ulmonary vascular resistance, decreased fluid and blood
equirements and less edema, decreased levels of renin and
ngiotensin, increased urine output and creatinine clearance,
ecreased thromboxane and increased prostacyclin levels,
nd attenuation of histologic changes associated with isch-
mia in brain tissue. More importantly, because LVADs are
eing used more frequently in destination therapy, any
dverse effects of inadequate arterial pulsatility on periph-
ral structures might be greatly magnified with the long
mplantation periods associated with this type of therapy.
In this study the pulsatility achieved with CF LVADs
as compared with that generated by PF LVAD support in
atients with heart failure at the time of LVAD implanta-
ion. Also, the pulsatility in patients with normal ventricular
unction was determined to provide a normal control refer-
nce. Pulsatility was quantified by using energy-equivalent
ressure (EEP) and surplus hemodynamic energy (SHE)
Abbreviations and Acronyms
AoF  aortic flow
AoP  aortic pressure
CF  continuous flow
EEP  energy-equivalent pressure
LVAD left ventricular assist device
MAP mean arterial pressure
PF  pulsatile flow
SHE  surplus hemodynamic energyalues calculated from hemodynamic waveform measure- a
18 The Journal of Thoracic and Cardiovascular Surgery ● Febrents obtained intraoperatively. These metrics have been
hown to provide a more physiologically relevant measure of
ulsatility than the commonly reported pulse pressure.16-19
lso, the arterial load, as seen by the heart, was quantified
y calculating the vascular input impedance. We hypothe-
ized that with increasing CF LVAD support, pulsatility
ould diminish and afterload would increase, whereas PF




wo groups of patients were enrolled for this investigation:
atients with normal cardiac function scheduled for coro-
ary artery bypass grafting and patients with heart failure
cheduled for LVAD implantation. The study was approved
y the institutional review board at Jewish Hospital (Lou-
sville, Ky) and Advocate Christ Medical Center (Oak
awn, Ill), and written informed consent was obtained from
ll participating patients. The healthy group consisted of
atients in New York Heart Association class I with normal
entricular function, which was defined as having no myo-
ardial damage and an ejection fraction of greater than 50%,
nd who were undergoing 1- to 3-vessel coronary artery
ypass grafting surgery. All patients with heart failure were
n New York Heart Association class IV. The type of LVAD
PF or CF) each patient with heart failure received was
ecorded, along with the cause of the cardiac disease, indi-
ation for LVAD implantation, and other pertinent descrip-
ive data.
tudy Protocol
igh-fidelity hemodynamic waveforms were collected in-
raoperatively in the healthy patient group and in the heart
ailure groups at the time of PF or CF LVAD implantation.
fter achievement of anesthesia and immediately before
nitiating cardiopulmonary bypass, a transit-time flow probe
Transonics Systems, Ithaca, NY) was placed around the
ortic root for measurement of aortic flow (AoF). A dual-
ipped, high-fidelity micromanometer catheter (Millar In-
truments, Houston, Tex) was inserted into the aorta for
imultaneous measurement of aortic and left ventricular
ressures through a small incision made in the blood vessel
note: the same incision is used later in the procedure for
nserting the infusion line for cardioplegia solution), se-
ured with a purse-string suture, and passed retrograde
hrough the aortic valve. Baseline hemodynamic waveforms
ere collected at the native heart rate and at paced heart
ates (80, 100, and 120 beats/min) in the healthy patient and
eart failure groups. In the heart failure groups, after the
VAD implantation and verification of the LVAD operation
15-45 minutes), transit-time flow probes were placed
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Poot or immediately downstream of the outflow cannula.
he pressure catheter was also reinserted. Simultaneous
emodynamic measurements were recorded over a range of
VAD flow rates and with the LVAD temporarily turned
ff. LVAD flow was varied by either adjusting pump rate
PF LVAD) or rpm (CF LVAD).
ata Collection and Analysis
emodynamic data were signal conditioned and analog-to-
igitally converted at a sampling rate of 400 Hz in 15-
econd recording epochs and stored for digital analysis with
clinically approved Good Laboratory Practices–compliant
ata acquisition system.20,21 All transducers were postcali-
rated against known standards to ensure measurement ac-
uracy. Pressure and flow waveforms were used to calculate
eart rate, stroke volume, cardiac output, mean aortic pres-
ure (AoP), LVAD flow, EEP, SHE, and vascular input
mpedance by using a Hemodynamic Evaluation and As-
essment Research Tool program22 developed in Matlab
MathWorks, Natick, Mass). Hemodynamic parameters
ere calculated on a beat-to-beat basis, with all beats in
ach data set averaged to obtain a single representative
ean value. Hemodynamic parameter values for healthy
nd heart failure baseline values and CF and PF LVAD
roups, expressed as means  standard error of the mean,
able 1. Demographics of patients with normal ventricular
ow or pulsatile-flow left ventricular assist devices
atient no. Sex Age (y) Heig
(n  8) 5M, 3F 62 16 171
F (n  10) 7M, 3F 51 13 174
F (n  12) 8M, 4F 56 13 176
ata are expressed as means  standard deviations. BSA, Body surface
F, pulsatile flow.
able 2. Heart rate, surplus hemodynamic energy, energy-e
ulsatile energy for normal baseline, failure baseline, and
ondition Device HR (beats/min) SHE (ergs
ormal baseline — 69 5 20,789
ailure baseline CF 103 8 17,919
PF 82  4 15,380
ow VAD flow CF 93 13 1378
PF 81  14 20,270
igh VAD flow CF 103 11 671
PF 72  10 31,011
ll results are expressed as means  standard error of the mean for all pat
eft ventricular assist device (LVAD) baseline values were not statistically disc
F LVADs for low (P .001) and high (P .000001) flow rates were statisticall
upport were not statistically discernible (P .4), suggesting the restoration o
ormal baseline and high PF VAD support were statistically significant (P 
ifferences in SHE values between failure baseline and low and high CF VAD
alues in all CF VAD support modes. HR, Heart rate; EEP, energy-equivalent pressu
The Journal of Thoracicere compared. CF and PF LVAD groups were further
ategorized as low or high LVAD flow support. Low LVAD
ow support was defined as being the highest LVAD flow
ate with native heart still ejecting, as evidenced by positive
ortic root flow, positive left ventricular and AoP gradient,
nd opening of the aortic valve. High LVAD flow support
as defined as the LVAD flow rate setting without native
eart ejection through the aortic valve, as evidenced by no
ortic root flow, negative left ventricular and AoP gradient,
nd closed aortic valve. A single-tailed t test was performed
o determine statistical significance.
The EEP formula is defined as the ratio of the area
eneath the hemodynamic power curve  fpdt to the area
eneath the pump flow curve  fdt during each pulse
ycle23 or, alternatively, the hemodynamic energy per unit
olume of fluid pumped.16 It was calculated as follows:
EP   fpdt ⁄  fdt, where f is the pump flow rate (in
iters per minute), p is the AoP (in millimeters of mer-
ury), and dt indicates that the integration is performed
ver time (t). The units for the EEP are millimeters of
ercury, and as such, it is possible to compare the EEP
ith the mean arterial pressure (MAP). The SHE value is
alculated by multiplying the difference between the EEP
nd MAP values by the conversion factor 1332 as follows:
tion and patients with heart failure receiving continuous-
) Weight (kg) BSA EF (%)
89  15 2.0 0.3 62  10
79  21 1.9 0.3 17  3
90  21 2.1 0.3 16  5
EF, ejection fraction; N, normal ventricular function; CF, continuous flow;
alent pressure, mean arterial pressure, and percentage of
and high LVAD flow rates
EEP (mm Hg) MAP (mm Hg) (EEP/MAP-1) * 100 (%)
80.4 4.1 64.8 3.3 24
77.6 2.8 64.2 2.2 21
82.4 7.5 70.8 7.4 16
75.2 8.0 74.1 7.7 2
80.8 13.0 65.5 10.1 23
79.8 5.3 79.3 5.3 6
95.7 10.2 72.4 10.8 32
n a group. Differences between continuous-flow (CF) and pulsatile-flow (PF)
e. Differences in surplus hemodynamic energy (SHE) values between CF and
ificant. Differences in SHE values between normal baseline and low PF LVAD
al SHE values with low PF VAD support. Differences in SHE values between
suggesting the augmentation of SHE values beyond normal baseline values.




















suppre; MAP, mean arterial pressure; VAD, ventricular assist device.
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CSPHEergs ⁄cm3  1332 fpdt ⁄  fdtMAP . This rep-
esents the extra energy required for generation of PF in
erms of energy (not pressure) units and is thus a physio-
ogically relevant measure of pulsatility because the gener-
tion of PF in the body is dependent on an energy gradient
ather than a pressure gradient.23-27
AoP and AoF waveform recordings were used to calcu-
ate systemic vascular input impedance at baseline and over
he range of LVAD flow rates. During LVAD support, the
oF was calculated as the sum of LVAD and aortic root m
20 The Journal of Thoracic and Cardiovascular Surgery ● Febrows. Using 15-second data epochs, the AoP and AoF wave-
orms were converted from time to frequency domain by using
ourier analysis algorithms in Matlab (MathWorks). The mag-
itudes and phases of the impedance for up to 15 harmonics
ere then calculated as the ratio of the magnitudes of AoP
nd AoF at each harmonic and the difference between the
hases of AoP and AoF at each harmonic, respectively. An
ncertainty analysis was also performed to estimate the
rror in the input impedance terms resulting from experi-
Figure 1. Aortic pressure (AoP, dotted
line), left ventricular pressure (LVP, solid
line), aortic distal flow (AoF), and left
ventricular assist device (LVAD) flow
(VADF) waveforms for low and high pul-
satile-flow (PF) LVAD flow support con-
ditions. At low PF LVAD support, the na-
tive heart still ejects through the aortic
valve, as evidenced by a positive left
ventricular and aortic pressure gradient
and significantly increased aortic distal
flow during the positive pressure gradi-
ent. At high PF LVAD flow support, the
native heart does not eject through the
aortic valve, as evidenced by a negative
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Pesults
ight healthy patients (5 men and 3 women) and 22
atients with heart failure (15 men and 7 women) were
nrolled in this study between September 2004 and
arch 2006 at the Jewish Hospital Heart and Lung
nstitute (Louisville, Ky) and Advocate Christ Medical
enter (Oak Lawn, Ill). In the group of healthy patients,
he ejection fraction was 62%  10%. In the group of
atients with heart failure, 11 patients had ischemic car-
iomyopathy, and 11 patients had idiopathic cardiomy- r
The Journal of Thoracicpathy. The indications for implantation were 12 for
ridge to transplantation, 9 for destination therapy, and 1
or bridge to recovery. Twelve patients received a PF
VAD (Thoratec HeartMate XVE, n  9; Thoratec
VAD, n  3), and 10 patients received a CF LVAD
Thoratec HeartMate II, n  7; MicroMed DeBakey, n 
). At the time of this writing, 1 patient had the LVAD
emoved on myocardial recovery, 5 had undergone trans-
lantation, 7 had died during support, and 9 were still
Figure 2. Aortic pressure (AoP, dotted
line), left ventricular pressure (LVP, solid
line), aortic distal flow (AoF), and left ven-
tricular assist device (LVAD) flow (VADF)
waveforms for low and high continuous-
flow (CF) LVAD flow support conditions. At
low CF LVAD support, the native heart still
ejects through the aortic valve, as evi-
denced by a positive left ventricular and
aortic pressure gradient and significantly
increased aortic distal flow during the
positive pressure gradient. At high CF
LVAD flow support, the native heart does
not eject through the aortic valve, as ev-
idenced by a negative left ventricular and
AoP gradient.eceiving LVAD support, with the average duration of
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CSPupport being 234  181 days. The demographics for
ach patient group are summarized in Table 1.
Patients with left ventricular failure had reduced car-
iac output, EEP, and SHE values and an increased heart
ate at baseline compared with patients with normal left
entricular function (Table 2). Differences in the MAP
alues between healthy and heart failure baseline patients
ere statistically insignificant (Table 2), and therefore
omparisons of SHE values between groups are valid
ecause the MAP value is fundamentally similar in all
atients studied.
Support with a PF or CF LVAD restored systemic blood
ow (combined aortic and LVAD blood flow) to normal
aseline values. The hemodynamic waveforms suggest a
iminished level of vascular pulsatility still exists with CF
VAD support, even at high LVAD flow rates; however,
ulsatility appears much greater with PF LVAD support, as
hown in Figures 1 and 2. Support with a PF LVAD
ugmented SHE and EEP values to normal baseline values,
hereas CF LVAD support diminished SHE and EEP val-
es (Figure 3). At low support levels, PF LVAD restored
HE values to within 2.5% of baseline normal SHE values,
hereas CF LVAD diminished SHE values by more than
3% of the normal baseline value. This effect was even
ore pronounced at high ventricular assist device flow rates
igure 3. Comparison of surplus hemodynamic energy (SHE) be-
ween baseline normal, baseline failure, and failing left ventri-
les with low and high ventricular assist device (VAD) support.
lthough pulsatile-flow (PF) and continuous-flow (CF) left ven-
ricular assist devices (LVAD) both restore flow, only the PF LVAD
estores SHE value to normal baseline values, whereas CF LVAD
ecreases SHE values considerably. Differences in SHE values
etween CF and PF LVADs for low (P < .001) and high flow rates
P < .00001) were statistically significant. These data indicate a
undamental difference between levels of pulsatility achieved
uring CF and PF LVAD support.ecause the PF LVAD augmented SHE values by 49% over C
22 The Journal of Thoracic and Cardiovascular Surgery ● Febraseline normal values, whereas the CF LVAD diminished
HE values by 97% (Figure 4).
The systemic vascular resistance, indicated by the im-
edance magnitude at 0 Hz (zero harmonic), decreased from
ailure baseline values with PF LVAD support, whereas
ascular resistance increased from failure baseline values
ith CF LVAD support (Figure 5, A). Also, vascular im-
edances in patients with PF and CF LVADs at baseline and
n patients with PF LVADs during support have a negative
hase for the first few harmonics, which reflects normal
ascular compliance, whereas impedance in patients with
igure 4. Comparison of percentage change in surplus hemody-
amic energy (SHE) from baseline normal values for baseline
ailure and failing left ventricles with low and high left ventric-
lar assist device (LVAD) support conditions. Heart failure causes
decrease in SHE values. Although pulsatile-flow (PF) and con-
inuous-flow (CF) LVADs both restore flow, only the PF LVAD
estores SHE values to normal baseline values or higher, whereas
he CF LVAD decreases SHE values considerably. These data
ndicate a fundamental difference between levels of pulsatility
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Prst few harmonics, which reflects a loss of compliance (or
stiffening”) of the vasculature with CF LVAD support
Figure 5, B).
iscussion
he results of this study unequivocally establish that there
re substantial differences in the arterial pulsatility provided
y PF and CF LVAD support at the time of device implan-
ation. SHE values are diminished during ventricular failure
ompared with normal baseline values because of the loss of
ontractility and stroke work of the native ventricle. Fur-
igure 5. Comparison of vascular impedance between baseline
ailure and failing left ventricles supported by pulsatile-flow (PF)
r continuous-flow (CF) left ventricular assist devices (LVAD) for
he first 6 harmonics. A, Vascular resistance, indicated by the
agnitude at 0 Hz, decreases with PF LVAD support, whereas
ascular resistance increases with CF LVAD support. B, Baseline
nd PF LVAD support have a negative phase for the first few
armonics, indicating normal vascular compliance. CF LVAD sup-
ort has a positive phase during the first few harmonics, indicat-
ng a stiffening of the vasculature with CF LVAD support. The
ifferences in vascular response to CF and PF LVAD support might
ave a significant effect on the myocardial load during LVAD
eaning and might potentially affect patient outcomes.hermore, even at low levels, PF LVAD support restored
The Journal of ThoracicHE and EEP values to normal baseline values. The phys-
ologic effects of augmenting SHE and EEP values over
ormal baseline values, as measured during maximal PF
VAD support, are unknown. CF LVAD support caused a
rastic reduction of SHE values, even at low levels of
VAD support, despite intermittent ejection through the
ortic valve. The diminished levels of SHE and EEP with
F LVAD support are more reflective of a nonpulsatile
aveform, contrary to what might be perceived visually in
igures 1 and 2. This strongly suggests that instead of
llowing near-physiological pulsatility during modest sup-
ort, as previously reported,12 circulatory support with a CF
VAD substantially reduces pulsatility from its physiolog-
cal levels, as demonstrated by SHE values that are de-
reased dramatically (93% in low support and 97% in high
upport) from normal baseline values. These results are in
greement with previous in vitro18 and animal19 studies,
hich have shown that CF LVAD support significantly
iminishes vascular pulsatility.
We hypothesize that prolonged diminished pulsatility
ight lead to vascular stiffening that increases ventricular
orkload, reduces myocardial perfusion because of early
systolic) AoP wave reflections, and attenuates baroreflex
ensitivity. Our results indicate that vascular impedance was
educed with PF LVAD support but was increased with CF
VAD support. However, our results are only indicative of
cute vascular responses to LVAD support because our
emodynamic data were obtained at the time of device
mplantation. An extended temporal study of arterial pulsa-
ility in chronic CF LVAD support by Potapov and col-
eagues12 in 2000 showed that although pulsatility was low
mmediately postoperatively, which is reflective of the non-
ulsatile flow generated by the device and similar to our
ndings, pulsatility steadily increased in all patients studied
ver the course of CF LVAD support. The authors attributed
he increase in pulsatility to increased contractility and
artial recovery of the unloaded left and right ventricles.
lthough myocardial recovery can improve pulsatility, vas-
ular stiffening without any improvement in myocardial
unction can also lead to an increase in pulsatility. Because
yocardial recovery occurs only in a relatively small frac-
ion of adults receiving LVAD support, we hypothesize that
steady chronic increase in vascular pulsatility can be
ttributed to vascular stiffening caused by long-term CF
VAD support. An extended temporal investigation of car-
iovascular hemodynamic data obtained at the time of de-
ice implantation and explantation is currently underway to
est this hypothesis.
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